Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals. The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world. Read More
The financial markets are once again in the throes of earnings season, a period that consistently proves to be a crucible for individual stock valuations and a significant driver of broader market sentiment. Recent corporate earnings reports, spanning from late 2024 through the third quarter of 2025, have painted a
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.
Shares of animal health company Zoetis (NYSE:ZTS)
fell 12.6% in the morning session after the company reported mixed third-quarter results and cut its full-year sales forecast. Although its adjusted earnings of $1.70 per share beat Wall Street's estimates, revenue of $2.4 billion was flat year-over-year and met expectations. More concerning for investors, Zoetis lowered its full-year revenue guidance to a midpoint of $9.44 billion, a 0.9% decrease from its previous forecast. The company's operating margin also compressed, falling to 37% from 38.3% in the same quarter last year. Ultimately, the lowered sales outlook and margin pressure overshadowed the earnings beat.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends.
Animal health company Zoetis (NYSE:ZTS) met Wall Streets revenue expectations in Q3 CY2025, but sales were flat year on year at $2.4 billion. On the other hand, the company’s full-year revenue guidance of $9.44 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.70 per share was 4.8% above analysts’ consensus estimates.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Zoetis Inc. (NYSE: ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026.
Zoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing interval approved for the alleviation of pain associated with osteoarthritis (OA) in cats.
Zoetis Inc. (NYSE: ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
